Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AB SCIEX Announces Biologics Initiative

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
Mass spectrometry leader’s BiologicsFocus programs address industry shift to biopharmaceuticals.

AB SCIEX has announced a global initiative focused on biologics. This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development.

AB SCIEX’s BiologicsFocus Initiative consists of four components: new product development; beta software evaluation program; one-on-one connections program; and forums for sharing the latest advancements in biologics across the scientific community.

The company revealed this initiative at the International Mass Spectrometry Conference (IMSC) in Japan.

The BiologicsFocus Initiative represents AB SCIEX’s open approach to producing comprehensive biologics solutions by involving scientists in industry and academia in the development of new tools.

AB SCIEX already has a proven track record with its TripleTOF technology for bio-therapeutics characterization.

The company is now taking the next important step to address an industry-wide need - the development of data analysis solutions to simplify and accelerate biologics development.

Forty-two percent of new drugs in drug development pipelines of pharmaceutical companies are based on biologics, according to survey results published earlier this year by EvaluatePharma, a market research firm.

Moreover, the development of biosimilars, or “generic” biologic drugs, is dramatically increasing globally in response to legislation enabling their licensure in the United States.

The trend is to transition away from the traditional model of drug development, which is based on small molecule analysis.

The promise of biopharmaceuticals is that pharmaceutical companies will be able to more rapidly develop more effective drugs with fewer side effects.

Recent advancements in technologies for large molecule analysis, such as protein characterization, have sped up the shift to bio-therapeutics.

AB SCIEX’s biologics initiative includes the following programs:

• BiologicsFocus Innovation - AB SCIEX is developing a suite of new products specifically for biologics. Because data analysis is considered to be a bottleneck for this type of analysis, the company is focusing on software development in the first phase of this initiative to eliminate this bottleneck.

• BiologicsFocus Eval - AB SCIEX is actively developing new biologics characterization software. To participate in a beta software evaluation program, go to www.absciex.com/biologics.

• BiologicsFocus Summits - AB SCIEX will host information-sharing forums or “summits” as special events that will bring together opinion leaders who are driving the evolution of biopharmaceuticals. This will also include an advisory network of scientists to provide input and feedback for ongoing product development.

• BiologicsFocus Connections - AB SCIEX will connect biologics researchers one-on-one with each other to cultivate new collaborations and advance this field of pharmaceutical science.

“We recognize biologics for its strategic importance to the pharmaceutical industry,” said Rainer Blair, President of AB SCIEX.

Blair continued, “AB SCIEX is well-positioned with our industry-leading hardware platforms and our unique combination of strengths in both large molecule characterization and pharmaceutical analysis. We are working closely with pharmaceutical scientists to develop and shape new software solutions that directly address the needs and requirements for the new frontier of drug discovery and development. We continue to be a trusted partner with pharmaceutical companies and academics worldwide.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Friday, June 17, 2016
SCIEX, QPS Holdings Collaborate
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification.
Wednesday, April 06, 2016
SCIEX, A*STAR’s BTI Launch Collaboration
Agreement aims to boost innovation of protein drugs that target new diseases and are safer for patients.
Wednesday, January 27, 2016
SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
AB SCIEX Wins New Product Innovation Award in Asia Pacific
The award recognizes the company’s continued innovation in the mass spectrometry industry and a number of new products introduced into the market in recent years.
Thursday, October 30, 2014
AB SCIEX, Dalton Pharma Services Announce ADC Partnership
Research collaboration aims to develop Antibody-Drug Conjugate analysis capabilities.
Wednesday, August 27, 2014
AB SCIEX to Present ESI-MS Workshop
The workshop will be presented at HPLC 2014.
Tuesday, April 22, 2014
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!